相关实验视频
Updated: Jun 29, 2025

05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.6K
探索卡利科辛对环素诱导心脏毒性的影响:一个网络药理学,分子对接和实验研究
Peng Zhu1, Qianqian Ren2,3, Ruizhi Zhang2,3
1Department of Hepatobiliary Surgery, Wuhan No.1 Hospital, Wuhan, China.
Frontiers in cardiovascular medicine
|April 5, 2024
概括
卡利科辛 (CA) 在预防化疗诱导的心脏毒性 (AIC) 方面表现有前途. 这项研究使用了网络药理学和分子对接来揭示CA.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 药理学 药理学是指药理学的学科.
- 生物信息学是一种生物信息学.
背景情况:
- 人环素化疗可以引起心脏毒性,这是癌症治疗中的一个重大问题.
- 人环素诱导的心脏毒性 (AIC) 需要研究预防和治疗策略.
- 来自Astragali Radix的Calycosin (CA) 正在研究其治疗AIC的潜力.
研究的目的:
- 阐明用卡利科辛 (CA) 减轻 antracycline 诱导的心脏毒性 (AIC) 的机制.
- 采用一种多维的方法,结合网络药理学,分子对接和体外实验.
- 为了确定潜在的分子点和途径参与CA的心脏保护作用.
主要方法:
- 网络药理学被用来确定CA和AIC的潜在目标.
- 使用Cytoscape构建和可视化了蛋白质与蛋白质相互作用网络.
- 分子对接评估了CA和确定目标之间的结合亲和力.
- 在体外实验验证了关键发现,包括ABCB1.1的作用.
- 路径丰富分析和基因组丰富分析 (GSEA) 探索了药理机制.
主要成果:
- 网络药理学确定了AIC中CA的多个标,包括TNF,ABCC1,TOP2A,ABCB1和XDH.
- 分子对接揭示了CA和ABCB1 (-7.5千卡/mol) 之间强大的结合能量.
- 在体外研究证实了在多克索鲁比治疗下ABCB1表达的显著变化.
- CA的抗AIC作用与氧化应激和炎症的调节有关.
结论:
- 综合网络药理和分子对接的生物信息学方法有效地确定了CA对AIC的治疗机制.
- 在体外实验证实了生物信息学预测.
- 卡利科辛 (CA) 显示出作为一种有前途的治疗剂的潜力,用于抗环素诱导的心脏毒性.
相关概念视频
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
500
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
500
Heart Failure Drugs: Inotropic Agents
578
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
578
Antihypertensive Drugs: Action of Calcium Channel Blockers
514
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
514
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
424
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
424
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K

